The Products Pipeline
Our Lead Compound GF-1002
mRNA-LNP expressing a centenarian variant of the SIRT6 gene. This method ensures that the gene does not integrate into the host DNA and poses no risk of self-replication. Also, it avoids the transfer of bacterial genetic material and mitigates concerns related to immune reactions or mutagenesis.
Pre Clinical Stage GF-1002
mRNA-LNP expressing SIRT6c.
Clinical Stage GF-1004
GF-1004 is a non-Human version of GF-1002 anti-aging gene therapy developed for veterinary use (dogs). SIRT6c is delivered via Plasmidic DNA
Pre Clinical Stage GF-1003
GF-1003 ﾠis an formulation of mRNA delivering SIRT6c to dermal fibroblasts
Clinical Programs
Clinical trial in aged dogs longevity and sarcopenia
The SLAB (Sarcopenia and Longevity in Aged Beagle dogs) clinical trial is a comparative randomized blinded trial conducted in 24 aged Beagles (+10 years) to assess efficacy and safety of pDNA SIRT6c for the treatment of sarcopenia and improvement of longevity.
Our Partners
Innovation requires collaboration with other leading organizations in longevity and gene delivery
